Clinical trials
Observational Endophthalmitis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Unknown status | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Terminated | 1 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asociación para Evitar la Ceguera en México | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Assiut University | 1 |
| Benha University | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Chiang Mai University | 1 |
| Fakultas Kedokteran Universitas Indonesia | 1 |
| Medical University of Graz | 1 |
| Minia University | 1 |
| National Eye Institute (NEI) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Endophthalmitis | 21 |
| Keratitis | 3 |
| Uveitis | 3 |
| Eye Infections | 2 |
| Inflammation | 2 |
| COVID-19 | 1 |
| Cataract | 1 |
| Conjunctivitis | 1 |
| Corneal Ulcer | 1 |
| Diabetic Retinopathy | 1 |
Trials
Showing 26 to 21 of 21. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.